Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Margolis

Showing results (141-150 of 219) with videos related to

Pageof 22
Sort By:
Future Medicinal Chemistry|July 2, 2015
Gold nanoparticles to improve HIV drug deliveryCarolina Garrido, Carrie A Simpson, Noelle P Dahl, et al.
AIDS (London, England)|June 6, 2008
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cellsNancy M Archin, Joseph J Eron, Sarah Palmer, et al.
JAMA|August 15, 2006
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppressionSusan Swindells, A Gregory DiRienzo, Timothy Wilkin, et al.
Cell Chemical Biology|December 22, 2023
A histone deacetylase network regulates epigenetic reprogramming and viral silencing in HIV-infected cellsJackson J Peterson, Catherine A Lewis, Samuel D Burgos, et al.
Plos Pathogens|February 26, 2021
Epigenomic characterization of latent HIV infection identifies latency regulating transcription factorsStuart R Jefferys, Samuel D Burgos, Jackson J Peterson, et al.
Cell|March 30, 2020
Curing HIV: Seeking to Target and Clear Persistent InfectionDavid M Margolis, Nancie M Archin, Myron S Cohen, et al.
The Journal of Infectious Diseases|November 17, 2006
Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138Michael M Lederman, Laura Smeaton, Kim Y Smith, et al.
Open Forum Infectious Diseases|May 17, 2024
Sequence Analysis of Inducible, Replication-Competent Virus Reveals No Evidence of HIV-1 Evolution During Suppressive Antiviral Therapy, Indicating a Lack of Ongoing Viral ReplicationSook-Kyung Lee, Amy Sondgeroth, Yinyan Xu, et al.
HIV Clinical Trials|August 14, 2003
Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adultsPeter J Ruane, David M Parenti, David M Margolis, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 12, 2016
Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical TrialJeffrey M Jacobson, Jean-Pierre Routy, Seth Welles, et al.
Pageof 22

Showing results (141-150 of 219) with videos related to

Sort By:
Pageof 22
Future Medicinal Chemistry|July 2, 2015
Gold nanoparticles to improve HIV drug deliveryCarolina Garrido, Carrie A Simpson, Noelle P Dahl, et al.
AIDS (London, England)|June 6, 2008
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cellsNancy M Archin, Joseph J Eron, Sarah Palmer, et al.
JAMA|August 15, 2006
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppressionSusan Swindells, A Gregory DiRienzo, Timothy Wilkin, et al.
Cell Chemical Biology|December 22, 2023
A histone deacetylase network regulates epigenetic reprogramming and viral silencing in HIV-infected cellsJackson J Peterson, Catherine A Lewis, Samuel D Burgos, et al.
Plos Pathogens|February 26, 2021
Epigenomic characterization of latent HIV infection identifies latency regulating transcription factorsStuart R Jefferys, Samuel D Burgos, Jackson J Peterson, et al.
Cell|March 30, 2020
Curing HIV: Seeking to Target and Clear Persistent InfectionDavid M Margolis, Nancie M Archin, Myron S Cohen, et al.
The Journal of Infectious Diseases|November 17, 2006
Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138Michael M Lederman, Laura Smeaton, Kim Y Smith, et al.
Open Forum Infectious Diseases|May 17, 2024
Sequence Analysis of Inducible, Replication-Competent Virus Reveals No Evidence of HIV-1 Evolution During Suppressive Antiviral Therapy, Indicating a Lack of Ongoing Viral ReplicationSook-Kyung Lee, Amy Sondgeroth, Yinyan Xu, et al.
HIV Clinical Trials|August 14, 2003
Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adultsPeter J Ruane, David M Parenti, David M Margolis, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 12, 2016
Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical TrialJeffrey M Jacobson, Jean-Pierre Routy, Seth Welles, et al.
Pageof 22